window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : April 26, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Neurodegeneration

  • Central Nervous System,Neurosciences,Pharmaceuticals and therapeutics,Research & Development

    Porosome reconstitution therapy reverses Alzheimer’s pathology in human brain organoids

    Porosome Therapeutics has reported preclinical results showing that restoring porosome [...]

    November 18, 2025
  • Clinical Trials,Pharmaceuticals and therapeutics

    Galimedix completes phase 1 trial of oral Alzheimer’s drug GAL-101

    Galimedix Therapeutics has completed a phase 1 study of its [...]

    September 14, 2025
  • Clinical studies,Mental health,Neurosciences

    From symptoms to biology: Neurodegeneration in the paraventricular thalamus in bipolar disorder

    Accumulation of neurodegenerative proteins could be key to understanding bipolar [...]

    September 8, 2025
  • Cell & Gene Therapy,Central Nervous System,Research & Development

    $2.5M awarded to fuel breakthrough research into tau-driven neurodegenerative diseases

    The Rainwater Charitable Foundation, Aging Mind Foundation, Alzheimer’s Association, and [...]

    August 15, 2025
  • Clinical Development,Drug Development,Precision medicine,Research & Development,Technology and platforms

    AltPep data highlights potential of intranasal peptide for early-stage Alzheimer’s

    AltPep Corporation has presented new preclinical findings at the Alzheimer’s [...]

    July 28, 2025
  • Artificial Intelligence,Drug Development,Patient Centricity,Technology and platforms

    Prenuvo research links alcohol and exercise to early brain and organ changes in asymptomatic adults

    Two new studies presented at the 2025 ISMRM Annual Meeting [...]

    June 27, 2025
  • Partnerships & Funding,Rare Diseases

    Chiesi and Key2Brain extend global partnership to advance blood-brain barrier-crossing therapies for ultra-rare diseases

    Chiesi Group has signed a worldwide license agreement with Swedish [...]

    June 12, 2025
  • Artificial Intelligence,Biologics & Biosimilars,Drug Development

    Alchemab strikes $415m licensing deal with Lilly for ALS candidate ATLX-1282

    UK-based Alchemab Therapeutics has signed a landmark licensing agreement with [...]

    May 20, 2025
  • Clinical Trials,Drug Development

    FTD trial milestone reached as Vesper Bio enrols first asymptomatic GRN carriers

    Vesper Bio has reached a key enrolment milestone in its [...]

    May 12, 2025
  • Partnerships & Funding

    PacBio Joins Davos Alzheimer’s collaborative to expand dementia research in North Africa

    PacBio has been selected as a technology partner by the [...]

    April 25, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Neomorph raises $100 million to advance NEO-811 Phase 1/2 cancer trial and molecular glue degrader pipeline
    Categories: Biotech, Clinical Trials, Drug discovery, Funding, Oncology, Partnerships & Funding, Pharmaceuticals and therapeutics, Research & Development, Technology and platforms
  • NICE expands Lokelma access for hyperkalaemia after draft recommendation
    Categories: Cardiovascular diseases, Chronic diseases, Market Access & Commercialization, Pharmaceuticals and therapeutics, Regulatory Affairs
  • Oncodesign expands ARRONAX deal to secure astatine-211 supply for radiotherapy research
    Categories: CDMOs & Manufacturing, Drug Development, European biotech, Logistics and distribution, Oncology, Partnerships & Funding, Supply Chain & Logistics
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top